Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function.

Nagasu H, Sogawa Y, Kidokoro K, Itano S, Yamamoto T, Satoh M, Sasaki T, Suzuki T, Yamamoto M, Wigley WC, Proksch JW, Meyer CJ, Kashihara N.

FASEB J. 2019 Nov;33(11):12253-12263. doi: 10.1096/fj.201900217R. Epub 2019 Aug 30.

2.

Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.

Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto M, Ward KW.

Drug Des Devel Ther. 2019 Apr 17;13:1259-1270. doi: 10.2147/DDDT.S193889. eCollection 2019.

3.

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ.

Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.

4.

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers.

Reisman SA, Goldsberry AR, Lee CY, O'Grady ML, Proksch JW, Ward KW, Meyer CJ.

BMC Dermatol. 2015 Jul 14;15:10. doi: 10.1186/s12895-015-0029-7.

5.

Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis.

Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW.

Radiat Res. 2014 May;181(5):512-20. doi: 10.1667/RR13578.1. Epub 2014 Apr 10.

PMID:
24720753
6.

Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.

Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW.

Arch Dermatol Res. 2014 Jul;306(5):447-54. doi: 10.1007/s00403-013-1433-7. Epub 2013 Dec 22.

PMID:
24362512
7.

The use of the African green monkey as a preclinical model for ocular pharmacokinetic studies.

Glogowski S, Ward KW, Lawrence MS, Goody RJ, Proksch JW.

J Ocul Pharmacol Ther. 2012 Jun;28(3):290-8. doi: 10.1089/jop.2011.0164. Epub 2012 Jan 11.

PMID:
22235843
8.

Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.

Donnenfeld ED, Comstock TL, Proksch JW.

J Cataract Refract Surg. 2011 Jun;37(6):1082-9. doi: 10.1016/j.jcrs.2010.12.046.

PMID:
21596251
9.

Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys.

Proksch JW, Lowe ER, Ward KW.

Drug Metab Dispos. 2011 Jul;39(7):1181-7. doi: 10.1124/dmd.111.039099. Epub 2011 Mar 25.

PMID:
21441467
10.

Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.

Proksch JW, Ward KW.

J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58. doi: 10.1089/jop.2010.0054.

PMID:
20874668
11.

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.

Torkildsen G, Proksch JW, Shapiro A, Lynch SK, Comstock TL.

Clin Ophthalmol. 2010 Apr 26;4:331-41.

12.

Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.

Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW.

J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116.

PMID:
19492955
13.

A rapid and sensitive LC/MS/MS assay for the quantitation of brimonidine in ocular fluids and tissues.

Jiang S, Chappa AK, Proksch JW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):107-14. doi: 10.1016/j.jchromb.2008.11.009. Epub 2008 Nov 13.

PMID:
19109079
14.

Nonclinical safety and pharmacokinetics of intravitreally administered human-derived plasmin in rabbits and minipigs.

Proksch JW, Driot JY, Vandeberg P, Ward KW.

J Ocul Pharmacol Ther. 2008 Jun;24(3):320-32. doi: 10.1089/jop.2007.0120.

PMID:
18476803
15.

Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry.

Arnold DR, Granvil CP, Ward KW, Proksch JW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 1;867(1):105-10. doi: 10.1016/j.jchromb.2008.03.025. Epub 2008 Apr 1.

PMID:
18417430
16.
17.

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.

Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR.

Drug Metab Dispos. 2004 Feb;32(2):172-7.

PMID:
14744938
18.

A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats.

Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, Owens SM.

J Pharmacol Exp Ther. 2002 Jul;302(1):119-26.

PMID:
12065708
19.

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man.

Ward KW, Proksch JW, Gorycki PD, Yu CP, Ho MY, Bush BD, Levy MA, Smith BR.

Xenobiotica. 2002 Mar;32(3):235-50.

PMID:
11958562
20.

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics.

Ward KW, Proksch JW, Salyers KL, Azzarano LM, Morgan JA, Roethke TJ, McSurdy-Freed JE, Levy MA, Smith BR.

Xenobiotica. 2002 Mar;32(3):221-33.

PMID:
11958561
21.

SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR.

Pharm Res. 2001 Sep;18(9):1336-44.

PMID:
11683250
22.

Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics.

Ward KW, Proksch JW, Levy MA, Smith BR.

Drug Metab Dispos. 2001 Jan;29(1):82-8.

PMID:
11124234
23.
26.

Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.

Hardin JS, Wessinger WD, Proksch JW, Owens SM.

J Pharmacol Exp Ther. 1998 Jun;285(3):1113-22.

PMID:
9618414
27.

Nitric oxide generation by renal proximal tubules: role of nitric oxide in the cytotoxicity of lipid A.

Traylor LA, Proksch JW, Beanum VC, Mayeux PR.

J Pharmacol Exp Ther. 1996 Oct;279(1):91-6.

PMID:
8858980
28.

Effects of lipid A on calcium homeostasis in renal proximal tubules.

Proksch JW, Traylor LA, Mayeux PR.

J Pharmacol Exp Ther. 1996 Feb;276(2):555-60.

PMID:
8632321

Supplemental Content

Loading ...
Support Center